5 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.60 | $2.04 | +27.2% | Beat |
| Q1 2026 | 2026-03-31 | $1.43 | $1.58 | +10.4% | Beat |
| Q4 2025 | 2025-12-31 | $1.13 | $1.26 | +11.9% | Beat |
| Q3 2025 | 2025-09-30 | $1.52 | $1.63 | +6.9% | Beat |
| Q2 2025 | 2025-06-30 | $1.08 | $1.46 | +35.0% | Beat |
Earnings Beat Rate
Bristol Myers Squibb has beaten analyst EPS estimates in 5 of 5 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →